Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Non-metastatic
How you choose between letrozole or exemestane when patients have AIMSS with anastrozole in adjuvant breast cancer therapy?
Related Questions
With the recent FDA approval of adjuvant ribociclib, how are you deciding on between adjuvant ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
What adjuvant systemic therapy would you give a patient with pN2 nodal relapse of ER+/HER2- breast cancer now s/p ALND, after initial mastectomy, adjuvant TC, and 5 years of endocrine therapy?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score?
Is any hormonal monitoring necessary for males with breast cancer on adjuvant aromatase inhibitor and LHRH agonist (Lupron)?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
Do you have concerns about the generalizability of Oncotype testing/Mammaprint testing in making chemotherapy decisions for non-Caucasian women?
How would you approach adjuvant therapy for large (≥4 cm), node negative, HR+, HER2- breast cancer in an elderly woman with comorbidities including neuropathy?
